Workshop/conference report on EMA draft guideline on validation of bioanalytical methods
Henning Blume1, Erich Brendel, Margarete Brudny-Klöppel
1SocraTec CSC GmbH, Oberursel, Germany. h.h.blume@t-online.de
Abstract:
This is a summary report of the workshop on the EMA Draft Guideline on Validation of Bioanalytical Methods held April 15-16th 2010 in Brussels (Belgium) and jointly organised by the European Bioanalysis Forum (EBF) and the European Federation for Pharmaceutical Sciences (EUFEPS). Aim of the workshop was to discuss the current scientific knowledge in the area of bioanalysis, the regulatory requirements with special focus on the new Draft Guideline and their subsequent implementation to the work in bioanalytical laboratories. Comments on the Draft Guideline were presented and discussed with representatives from regulatory authorities in Europe. The workshop started with discussions on the scope of the Guideline and the need for implementation of GLP. A special focus was set on method validation of chromatographic procedures and subsequent study sample analysis. In addition, requirements for ligand-binding assays were briefly addressed. Intention of this Conference Report is to summarise important aspects of the discussions in order to draw certain conclusions, and to identify points which remain open and may require clarification at a later stage.
Related Concept Videos
Data Validation
Key parameters for method validation include:
In Vitro Drug Release Testing: Overview, Development and Validation
Development of Analytical Methods
Clinically Relevant Drug Product Specifications: Methods of Establishment
Therapeutic Drug Monitoring: Drug Analysis Methods
Bioavailability Study Design: Healthy Subjects Versus Patients

